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MineralizationThe role of serum amyloid A (SAA) proteins, which are ligands for toll-like receptors, was analyzed in human
bone marrow-derived mesenchymal stem cells (hMSCs) and their osteogenic offspring with a focus on
senescence, differentiation and mineralization. In vitro aged hMSC developed a senescence-associated secretory
phenotype (SASP), resulting in enhanced SAA1/2, TLR2/4 and proinﬂammatory cytokine (IL6, IL8, IL1β, CXCL1,
CXCL2) expression before entering replicative senescence. Recombinant human SAA1 (rhSAA1) induced SASP-
related genes and proteins in MSC, which could be abolished by cotreatment with the TLR4-inhibitor CLI-095.
The same pattern of SASP-resembling genes was stimulated upon induction of osteogenic differentiation,
which is accompanied by autocrine SAA1/2 expression. In this context additional rhSAA1 enhanced the
SASP-like phenotype, accelerated the proinﬂammatory phase of osteogenic differentiation and enhancedminer-
alization. Autocrine/paracrine and rhSAA1 via TLR4 stimulate a proinﬂammatory phenotype that is both part of
the early phase of osteogenic differentiation and the development of senescence. This signaling cascade is tightly
involved in bone formation and mineralization, but may also propagate pathological extraosseous calciﬁcation
conditions such as calcifying inﬂammation and atherosclerosis.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The primary response to inﬂammation, infection and tissue injury
is mediated by the innate immune system via toll-like receptors
(TLR1–6). TLRs bind a variety of ligands to transduce signals via
receptor-associated kinase systems such as p38 activation, NFκBd 1; frz, frizzled; hMSCs, human
grin-binding sialoprotein; IL1B,
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. This is an open access article undernuclear translocation and STAT signaling cascades, which trigger the
release of pro-inﬂammatory cytokines like IL1β, IL6 and members of
the CCL and CXCL families of cytokines (Kang and Lee, 2011; Brown
et al., 2011) that recruit cells of the adaptive immune system if
necessary.
The TLR family of receptors is tightly involved in the modulation of
functions of mesenchymal and other stem cells (Rolls et al., 2007).
Bonemarrow-derivedmesenchymal stem cells (MSCs) are the principal
source of bone regeneration.MSCs have been reported to express TLR1–
6 and MSC treatment with a cocktail of pro-inﬂammatory cytokines
especially upregulates TLR2, 3 and 4 expression in mice and humans
(Delarosa et al., 2012). The role of TLR in MSC biology has not yet
been completely unraveled and variably contrasting effects of TLR
activation on MSC biology have been reported. TLR2 activation
using the ligand Pam3Cys followed by NFκB nuclear translocation
completely abolished MSC multipotent differentiation capacity in mice
(Pevsner-Fischer et al., 2007), while depending on the time frame and
type of activation osteogenic differentiation was either inhibited or
enhanced (Huang et al., 2014; Mo et al., 2008; Raicevic et al., 2012;
Chang et al., 2013; Zhao et al., 2011). Hence the complete picture of
the role of TLR expression in MSC biology is just emerging (Delarosa
et al., 2012).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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inﬂammatory reaction following injury and an initial burst of growth
factors released by platelets from fracture hematoma (Kolar et al.,
2010; Gerstenfeld et al., 2003). Pro-inﬂammatory stimuli have been
reported to enhance osteogenic differentiation and bone healing but
may also inhibit bone formation dependingon the duration and the spe-
ciﬁc signaling stimulus (Mo et al., 2008; Raicevic et al., 2012; Chang
et al., 2013; Zhao et al., 2011).Moreover, osteogenic differentiation itself
stimulates the expression of TLR2 and 4 in hMSC (Kovacevic et al.,
2008). In murine and human MSCs TNFα stimulation and NFκB
activation have shown very inconsistent results with respect to osteo-
genic differentiation and bone healing depending e.g. on the origin of
MSC (adipose tissue versus bone marrow) and also the recruitment
and migration phases compared to later phases of bone healing
(Pevsner-Fischer et al., 2007; Huang et al., 2014; Raicevic et al., 2012).
Mineralization is an endpoint of osteogenic differentiation and bone for-
mation. However extra-osseous mineralization plays an important role
in chronic inﬂammatory and aging-associated degenerative diseases
such as atherosclerosis and sclerosing bone metastases (Hofbauer
et al., 2014). We have recently described the expression of WNT5A
in TNF and LPS-treated skeletal precursors and a subtle analysis of
WNT5A effects on murine MSC described an ampliﬁcation of pro-
inﬂammatory signals downstreamWNT5A (Rauner et al., 2012). Immu-
nohistochemistry analyses of atherosclerotic lesions also revealed
marked expression ofWNT5A in such areas, consistentwith the hypoth-
esis that atherosclerosis is a chronic inﬂammatory disease (Christman
et al., 2008). Given the fact however that treatment with anti-TNF anti-
bodies under certain circumstances could stop arthritis but not the
extraosseous bone formation, there is still a different trigger to be
found for the inﬂammatory self-sustaining loop and this pathological
form of mineralization.
Replicative senescence is another condition that can be preceded
and propagated by a very similar cascade of proinﬂammatory signals,
which is called a senescence-associated proinﬂammatory phenotype
(SASP) (Velarde et al., 2013). Since this SASP can “infect” neighboring
cells a condition can be spread that is capable of impairing fundamental
processes of regeneration and lineage commitment.
Serum amyloid A proteins 1 and 2 (SAA1 and 2) are themajor acute-
phase proteins systemically secreted by the liver in response to inﬂam-
mation, trauma or infection but local expression was also detected in
various other tissues such as the bone, cartilage and vessels, as well as
in inﬂamed tissues and serum in osteoarthritis and atherosclerosis
(Kovacevic et al., 2008; Vallon et al., 2001; de Seny et al., 2013; Meek
et al., 1994; Eklund et al., 2012). SAA proteins are encoded by the
SAA1 and SAA2 genes, which seem to be coordinately expressed
(Thorn et al., 2004). Their transcription is induced by glucocorticoids
and cytokines like TNFα, IL1α, IL1β and IL6 (Kovacevic et al., 2008;
Vallon et al., 2001; Thorn et al., 2004; Hagihara et al., 2004). In turn
autocrine SAA was described to amplify the proinﬂammatory environ-
ment by again stimulating cytokine expression, e.g. IL6, IL8, and CXCL1,
and to induce the expression of metalloproteinases at the tissue level
(Vallon et al., 2001; de Seny et al., 2013). The signal transduction path-
ways SAA proteins can address are transmitted via TLR2 and 4 receptors
and via the formyl peptide receptor FPRL1 in various cell systems
(Cheng et al., 2008; Sandri et al., 2008; Dong et al., 2011; Su et al., 1999).
We show here that SAA is locally expressed in hMSC, its expression
is enhanced during both in vitro aging and normal osteogenic differen-
tiation and that by binding to TLR4 it further contributes to a self-
sustaining pro-inﬂammatory ampliﬁcation loop that consists of TLR4
activation via p38 kinase, NFκB activation by p65 phosphorylation and
downstream stimulation of pro-inﬂammatory cytokines. This micro-
milieu, when transient, can either support wnt/frz-related osteogenic
differentiation (Baron and Kneissel, 2013) or induce cellular aging and
senescence because it resembles a SASP phenotype. Hence SAA via
TLR4 activation may both be an enhancer of osteogenic differentiation
and a trigger of inﬂammation-associated calciﬁcation.2. Materials and methods
2.1. Cell culture and in vitro aging
Human MSCs were obtained from the bone marrow of femoral
heads according to the described protocol (Ebert et al., 2009) after
total hip arthroplasty due to osteoarthritis and/or hip dysplasia.
The procedure was approved by the local Ethics Committee of the
University of Würzburg. Brieﬂy, bone marrow preparations were
washed with Dulbecco's modiﬁed Eagle's medium (DMEM/F12)
(Life Technologies GmbH, Darmstadt, Germany) supplemented
with 10% heat-inactivated FCS (Biochrom GmbH, Berlin, Germany),
1 U/ml penicillin, 100 μg/ml streptomycin (all Life Technologies
GmbH), and 50 μg/ml ascorbate (Sigma-Aldrich GmbH, Munich,
Germany) and centrifuged at 1200 rpm for 5 min. The pellet was
reconstituted in medium and washed 4 times, and the supernatants
of the washing steps containing the released cells were collected.
Cells were centrifuged and cultivated at a density of 3 × 108 cells
per 150 cm2 culture ﬂask. Adherent cells were washed after 2 days
and cultivated until conﬂuence. Cells were grown at 37 °C in a hu-
midiﬁed atmosphere consisting of 5% CO2 and 95% air. For
long term cultivation, cells were expanded at 70–90% conﬂuence
by trypsinization with 1× trypsin–EDTA (Life Technologies GmbH)
and reseeding in a split ratio of 1:3 relative to the cell culture ﬂask
surface. This procedure was repeated until cells stopped prolifera-
tion and hMSC did not become conﬂuent within 3 weeks due to rep-
licative senescence. The time frame of this process was individually
different for each of the 8 hMSC donors used. The last, non-conﬂuent
passage was deﬁned as “passage x” (Px) (Px MSC1: P8; Px MSC2: P9;
Px MSC3: P10; Px MSC4 and 5: P11; Px MSC6: P12; Px MSC7: P15; Px
MSC8: P18).
2.2. Osteogenic differentiation of hMSC
Human MSCs were differentiated into the osteoblastic lineage by
seeding 1 × 104 cells per cm2 in 6-well plates for RNA isolation and
4-well Lab-Tek Chamber Slides (Nunc, Wiesbaden, Germany) for histo-
chemical staining. After reaching conﬂuence, medium was replaced by
osteogenic medium (OM) consisting of DMEM high glucose, 10% FCS,
1 U/ml penicillin, 100 μg/ml streptomycin (all Life Technologies
GmbH), 50 μg/ml L-ascorbic acid 2-phosphate, 1 μM dexamethasone
and 10 mM β-glycerophosphate (all Sigma Aldrich GmbH). Control
cells were kept in expansion medium. Inﬂuence of SAA, SAA in combi-
nation with the TLR4 inhibitor CLI-095, and CLI-095 alone on minerali-
zation and alkaline phosphatase (ALP) staining was tested by adding
1 μM rhSAA1 (PeproTech GmbH, Hamburg, Germany) and/or 1 μg/ml
of CLI-095 (InvivoGen, Toulouse, France) throughout the osteogenic dif-
ferentiation process. Medium was changed twice a week.
2.3. Histochemical staining
ALP was stained after 4 days or 2 weeks of differentiation using the
Alkaline Phosphatase, Leukocyte Kit 86-C (Sigma Aldrich GmbH) ac-
cording to the manufacturer's instructions. For the detection of calcium
hydrogen phosphate and hydroxylapatite in the extracellular matrix
hMSCs were ﬁxed in methanol after 7 days or 3 weeks, stained with
alkaline Alizarin Red S (1% w/v) (Chroma-Schmidt GmbH, Stuttgart,
Germany) for 2 min and air dried. Microscopic images were taken
at room temperature with an Axioskop 2 MOT microscope with a
10×/0.3 Plan Neoﬂuar objective and an AxioCam MRc camera (all Carl
Zeiss Microimaging GmbH, Göttingen, Germany). Staining was quanti-
ﬁed using the AutMess tool of the AxioVision Software (Carl Zeiss
Microimaging GmbH) by analyzing 6 to 20 randomly selected pictures
per preparation. Signiﬁcances were tested with the Wilcoxon signed-
ranks test.
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Total RNAwas isolated after 24 h of 0.1, 0.5, 1 and 2 μMrhSAA1 treat-
ment, costimulationwith 1 μMrhSAA1 andwith 1 μg/ml of the TLR4 sig-
naling inhibitor CLI-095 and after 1, 7 and 14 days of osteogenic
differentiation with and without 1 μM rhSAA1 treatment by using the
NucleoSpin RNA II Puriﬁcation Kit (Macherey-Nagel, Düren, Germany)
according to the manufacturer's instructions. For cDNA synthesis 1 μg
of total RNA was reverse transcribed with Oligo(dT)15 primers and
MMLV reverse transcriptase (both Promega GmbH, Mannheim,
Germany) according to the manufacturer's instructions. Quantitative
real-time PCR (qPCR) was performed using KAPA SYBR FAST Universal
2× qPCR Master Mix (Peqlab Biotechnologie GmbH) and 0.25 pmol
of sequence speciﬁc primers obtained from biomers.net GmbH
(Ulm, Germany) or Qiagen GmbH (Hilden, Germany) (see Table 1 for
primer sequences and PCR conditions). Results were calculated with
the efﬁciency-corrected Ct model (Pfafﬂ, 2001) with RPS27A as the
house-keeping gene. Signiﬁcance was tested with REST (Pfafﬂ et al.,
2002).
2.5. Western blot
Human MSCs were treated with 1 μM rhSAA1 for 30 and 60 min,
respectively and cotreated with the TLR4 inhibitor CLI-095. Cells were
washed twice with PBS and harvested in 200 μl lysis buffer (100 μM
HEPES, 10 mM KCl, 2 mM MgCl2, 1 mM DTT) containing cOmplete
protease inhibitor (Roche Diagnostics Deutschland GmbH, Mannheim,
Germany). 5 μl 10% Nonidet-P40 was added, followed by centrifugation
at 13,000 rpm, 4 °C for 30 s. Proteinswere quantiﬁed by RotiQuant assay
(Carl Roth GmbH, Karlsruhe, Germany). 15 μg protein was mixed with
3.75 μl loading buffer (RotiLoad, Carl Roth GmbH) and denaturated
by boiling for 5 min. Samples were separated by SDS polyacrylamideTable 1
PCR primers and conditions. Primer names, sequences, product lengths, annealing temperature
Gene Primer Sequence 5′–3′ Prod
CXCL1 CXCL1 qFOR GAAAGCTTGCCTCAATCCTG 88
CXCL1 qREV CACCAGTGAGCTTCCTCCTC
CXCL2 CXCL2 qFOR AGCTTATTGGTGGCTGTTCC 102
CXCL2 qREV ACACATTAGGCGCAATCCAG
IBSP Hs_IBSP_1_SG Qiagen sequence
IL1B IL1b qFOR AAACCTCTTCGAGGCACAAG 169
IL1b qREV GGCCATCAGCTTCAAAGAAC
Il6 Il6 qFOR AAAGCAGCAAAGAGGCACTG 108
Il6 qREV TTTTCACCAGGCAAGTCTCC
IL8 IL8 qFOR CATACTCCAAACCTTTCCAC 165
IL8 qREV TCAAAAACTTCTCCACAACC
OPG Hs_TNFRSF11B_1_SG Qiagen sequence
OP OP qFOR TATGATGGCCGAGGTGATAG 133
OP qREV CATTCAACTCCTCGCTTTCC
p16 p16 qFOR TGGACCTGGCTGAGGAGCT 107
p16 qREV GACCTTCCGCGGCATCTA
PTGS2 Hs_PTGS2_1_SG Qiagen sequence
ROR2 ROR2 qFOR CTGTGTGACGTACCCTCGTG 108
ROR2 qREV AGAAGAAAAGGCAAGCGATG
RPS27A RPS27A qFOR TCGTGGTGGTGCTAAGAAAA 141
RPS27A qREV TCTCGACGAAGGCGACTAAT
RUNX2 Runx2 qFOR CTTCACAAATCCTCCCCAAG 147
Runx2 qREV ATGCGCCCTAAATCACTGAG
SAA1 SAA1 qFOR GCAAAGACCCCAATCACTTC 127
SAA1 qREV GTACCCTCTCCCCGCTTTG
SAA2 SAA2 qFOR CGATCAGGCTGCCAATAAAT 124
SAA2 qREV GCCTCATAGCCAGGTCTCCT
TLR2 TLR2 qFOR GAGGCAGCGAGAAAGCG 318
TLR2 qREV CCATTGCGGTCACAAGA
TLR4 TLR4 qFOR TCCATTTCAGCTCTGCCTTC 114
TLR4 qREV TGGGACACCACAACAATCAC
WNT5A WNT5a qFOR GAAGCCAATTCTTGGTGGTC 190
WNT5a qREV GGCATTCTTTGATGCCTGTCgel electrophoresis on 0.8× MDE gels (Biozym, Hess. Oldendorf,
Germany), 375 mM Tris, pH 8.8, 0.1% SDS in 192 mM glycine, 25 mM
Tris, 0.1% SDS, pH 8.8. Proteins were electroblotted for 2 h at 20 V, 4 °C
to a stabilized nitrocellulose membrane (Optitran BA-S, Schleicher and
Schuell, Dassel, Germany) using a Mini Protean unit (BioRad, München,
Germany). Membranes were blocked with 2.5% nonfat milk powder in
TTBS buffer (0.1 M Tris, 150 mM NaCl, 0.1% Tween-20) and incubated
with phospho-p38 MAPK (#9215), p38α MAPK (#9217), phospho-
NFκB (p65 #3033), and NFκB p65 (#6956) (dilution 1:2000, all Cell Sig-
naling Technology Inc., Leiden, The Netherlands) primary antibodies di-
luted in blocking solution overnight at 4 °C. Membranes were washed
3× for 15minwith TTBS followed by incubation for 2 h at room temper-
ature with secondary anti-mouse or anti-rabbit IgG-horseradish perox-
idase antibodies, respectively (Santa Cruz Biotechnology, Inc.,
Heidelberg, Germany) diluted 1:2000 in TTBS solution. After another
washing 3× for 15 min with TTBS speciﬁc staining was detected using
the chemiluminescence (ECL) system (VWR International GmbH,
Darmstadt, Germany). All bands were densitometrically analyzed with
ImageJ.2.6. Enzyme linked immunosorbent assay
Human MSCs were stimulated with 1 μM rhSAA1 for 1 day or
cotreated with 1 μg/ml of the TLR4 inhibitor CLI-095. Supernatants
were harvested, diluted 1:20 (controls and CLI-095 treated samples)
and 1:50 (rhSAA1 treated samples) and IL-6 and IL-8 were determined
with ELISA (IL-6: 900-K16, IL8: 900-K18, both PeproTech GmbH)
according to the manufacturer's instructions. 3 independent MSC
preparations were used and values were normalized to IL-6 and IL-8
standard curves. Signiﬁcances were tested with the Mann–Whitney U
test.s and GenBank accession numbers are shown.
uct length (bp) Annealing temp (°C) GenBank accession number
57 NM_001511
60 NM_002089
57 NM_004967
57 NM_000576
60 NM_000600
60 BT007067
60 NM_002546
60 NM_001040058
58 NM_000077
59 NM_000963
59 NM_004560
60 NM_001135592
58 NM_001024630
57 M23699
60 AB937783
60 XM_005263194
57 NM_138554
60 XM_011534081
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3.1. SAA expression is associated with in vitro aging of hMSC
To analyze cellular senescence of bone-forming cells in vitro we per-
formed long-term cultivation of hMSC until cells stopped proliferation
as previously described (Benisch et al., 2012). The senescent state had
been veriﬁed by enhanced p16 expression in cells of the last, senescent
passage compared to the ﬁrst passage by Western blot analyses
(data not shown). The amount of time and number of passages until
growth arrest differed widely between hMSC populations of 8 different
donors with 8–15 cumulative population doublings and 8–18 passages,
respectively. Assuming that each hMSC population underwent an
in vitro aging process in its individual time course,wedivided the number
of passages until growth arrest into 4 equal quarters (Fig. 1A). RNA was
isolated and relative gene expression of SASP-associated genes was ana-
lyzed of cells at the end of the 1st, 2nd and 3rd quarters, the last prolifer-
ating passage (Px− 1) and the growth-arrested, senescent passage (Px).Fig. 1. Long-term cultivation ofMSC. Long term cultivated hMSCs develop a senescence-associat
serum amyloids SAA1 and SAA2. (A) HMSCs were cultured and expanded in vitro until they sto
different hMSC populations stopped to proliferate and were divided into 4 quarters. (B) qPCRw
(P1+n2), 3rd quarter (P1+n3), the last proliferating passage (Px− 1) and the growth-arreste
ratios compared to P1 of 8 hMSC populations ± SD. Due to undetectable gene expression in P1
***p b 0.001 by REST (Pfafﬂ et al., 2002). (CXCL1: chemokine (C–X–Cmotif) ligand 1; IL1B: inter
receptor superfamily, member 11b; p16: CDKN2A, cyclin-dependent kinase inhibitor 2A; SAA1Gene expressionwas compared to cells of the ﬁrst passage (P1) (Fig. 1B).
Over the time course of in vitro aging we detected continuously increas-
ing expression of p16 (CDKN2A) and SASP genes IL1B, IL6 and OPG. An
extreme increase in the expression of acute-phase SAA genes SAA1 and
SAA2was observed after two-thirds of cultivation time, which continued
to a lesser extent until the cells stopped proliferating. Furthermore, we
detected increased expression of the SAA receptor TLR4 in late passages.
Other known SASP genes, e.g. IL8 and CXCL2 (data not shown) were not
signiﬁcantly differentially expressed during in vitro aging.
3.2. rhSAA1 induces a senescence associated secretory phenotype in hMSC
through TLR4 signaling
To identify the optimal rhSAA1 concentration hMSCs isolated from 5
individual donors were treated with different doses of recombinant
human SAA1 (rhSAA1) for 24 h and IL-6 expression and IL-8 expression
were quantiﬁed by qPCR (Supplementary Fig. 1). 1 μg/ml was chosen as
the best concentration and was used in all experiments. To determine ifed secretory phenotype (SASP) over time and show anenhanced expression of acute phase
pped proliferation and entered cellular senescence. The numbers of passages varied until
as performedwith mRNA of passages at the end of the 1st quarter (P1+ n1), 2nd quarter
d, senescent passage (Px). Theﬁrst passage (P1) served as control. Dots show themeans of
of hMSC of one donor IL8 shows means of 7 hMSC populations. *p b 0.05, **p b 0.01, and
leukin 1 beta, IL6: interleukin 6, IL8: interleukin 8; OPG: TNFRSF11B, tumor necrosis factor
: serum amyloid A1; SAA2: serum amyloid A2; TLR4: toll-like receptor 4).
Fig. 2. rhSAA1 signaling pathway and target genes. rhSAA1 induces gene expression of SASP proteins via TLR4 through p38 and NFκB signaling pathways in hMSCs. (A) qPCR of hMSC
stimulated with 1 μM rhSAA1 for 24 h. Bars represent the mean change in gene expression ± SD of rhSAA1 treated 6 hMSC populations compared to untreated controls ± SD;
*p b 0.05, **p b 0.01, and ***p b 0.001 by REST (Pfafﬂ et al., 2002). (B) p38 and p65 (NFκB) phosphorylation after treating cells with 1 μM rhSAA1 for 30 and 60 min shown by Western
blot. Experiments were repeated twice, and representative stainings are shown. (CXCL1: chemokine (C–X–Cmotif) ligand 1; CXCL2: chemokine (C–X–Cmotif) ligand 2; IL1B: interleukin
1 beta, IL6: interleukin 6, IL8: interleukin 8; OPG: TNFRSF11B, tumor necrosis factor receptor superfamily, member 11b; p16: CDKN2A, cyclin-dependent kinase inhibitor 2A; PTGS2: pros-
taglandin-endoperoxide synthase 2; ROR2: receptor tyrosine kinase-like orphan receptor 2; SAA1: serum amyloid A1; SAA2: serum amyloid A2; TLR2: toll-like receptor 2; TLR4: toll-like
receptor 4; WNT5A: wingless-type MMTV integration site family, member 5A).
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the development of a senescence associated secretory phenotype
(SASP) in hMSC, we treated cells of 6 different donors in P1 with 1 μM
rhSAA1 for 24 h and analyzed gene expression by qPCR (Fig. 2A). We
could conﬁrm that rhSAA1 induces its own endogenous expression
(SAA1 and SAA2) as well as the expression of IL1B, IL6, IL8 and CXCL1,
as described in osteoarthritic ﬁbroblast-like synoviocytes (de SenyFig. 3. Toll-like receptor 4 mediates rhSAA1 effects in hMSC. (A) The TLR4 inhibitor CLI-095 di
staining of unphosphorylated p65 is depicted. Experiments were repeated twice, a representat
abrogated rhSAA1 effects on gene expression. Black bars represent themean change in gene ex
gray bars represent the mean change in gene expression + SD of rhSAA1 and CLI-095 cotrea
***p b 0.001 by REST (Pfafﬂ et al., 2002). (C) Cotreatment of cells with rhSAA1 and the TLR4
IL-8 (black bars) were determined in cell culture supernatants of 3 independent hMSC popul
1 day. Values are shown as means + SD (**p b 0.01 by Mann–Whitney U-test).et al., 2013). IL-6 and IL-8 secretion could also been quantiﬁed after
rhSAA1 stimulation by ELISA in 3 different hMSC donors (Fig. 3C).
The concentration of IL-6 increased signiﬁcantly from 7.3 ng/ml to
158 ng/ml after rhSAA1 treatment, while IL-8 was raised signiﬁcantly
from 1.9 ng/ml to 56 ng/ml. In addition we found enhanced expression
of the known SASP genes CXCL2 and OPG. We also observed an increase
in the expression of SAA receptors TLR2 and TLR4 and the non-canonicalminishes rhSAA1 effects on p65 phosphorylation after 30 min in hMSC. For normalization
ive image is shown. (B) Cotreatment of cells with rhSAA1 and the TLR4 inhibitor CLI-095
pression± SD of rhSAA1 treated 4 to 5 hMSC populations compared to untreated controls,
ted 4 to 5 hMSC populations compared to untreated controls; *p b 0.05, **p b 0.01, and
inhibitor CLI-095 abrogated rhSAA1 effects on cytokine secretion. IL-6 (white bars) and
ations treated with rhSAA1 or cotreated with rhSAA1 and the TLR4 inhibitor CLI-095 for
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tion were also investigated as mediators of TLR signaling (Brown et al.,
2011; DelaRosa and Lombardo, 2010; Yang et al., 2012). We found that
p38 and p65 phosphorylation occurred after 30 min treatment with
rhSAA1 in 3 different hMSC donors. A representative blot is shown
(Fig. 2B) where densitometrical analyses of bands revealed a 9-fold up-
regulation of p65 phosphorylation and a 24-fold upregulation of p38
phosphorylation after 30 min. Densities of phosphorylated proteins
were normalized to unphosphorylated controls.
3.3. rhSAA1 effects are mediated by TLR4 in hMSC
In order to dissect the downstream signaling mechanism of gene
regulation of rhSAA1/TLR4 we analyzed if the TLR4 signaling inhibitor
CLI-095 was able to abolish rhSAA1 effects on cellular signaling and
gene expression. Cotreatment of hMSC isolated from 3 donors with
rhSAA1 and the TLR4 inhibitor CLI-095 abolished the phosphorylation
of p65/NFκB induced by rhSAA1 alone after 30 min by Western blot.
Fig. 3A shows a representative image where rhSAA1 increased p65 phos-
phorylation more than 3-fold. Cotreatment of cells with rhSAA1 and CLI-
095 abrogated this effect (1.2-fold induction). Densities of phosphorylat-
ed proteins were normalized to unphosphorylated controls. Co-
stimulation of hMSC from 3 to 4 donors with CLI-095 and rhSAA1 signif-
icantly abrogated rhSAA1 effects on genes involved in non-canonical
wnt-signaling (WNT5A and the AP-1 target gene prostaglandin-
endoperoxide synthase 2 (PTGS2)) as well as the expression of the SASP
genes SAA1, IL6, IL1B and IL8 (Fig. 3B). On protein levels this effect could
be veriﬁed by the quantiﬁcation of IL-6 (Fig. 3C, white bars) and IL-8
(blackbars) by ELISA in cell culture supernatants of hMSC from4different
donors stimulated with rhSAA1 or cotreated with rhSAA1 and the TLR4
inhibitor CLI-095. IL-6 values were signiﬁcantly abrogated from
158 ng/ml (rhSAA1 treatment) to 45 ng/ml (rhSAA1 plus CLI-095),
while IL-8 concentrations were signiﬁcantly diminished from 56 ng/ml
(rhSAA1) to 11 ng/ml (rhSAA1 plus CLI-095). CLI-095 alone had no effect
on IL-6 or IL8 protein levels.
3.4. rhSAA1 stimulates non-canonical wnt signaling by inducing WNT5A
and accelerates osteogenic differentiation in vitro
To characterize SAA target genes in P1 hMSC we also analyzed the
expression of genes relevant for osteogenic differentiation upon stimu-
lation with rhSAA1 and found an increase inWNT5A expression and a
trend for ROR2 (Fig. 2A). To analyze if osteogenic effects were more
pronounced in conditions promoting osteogenic differentiation we
incubated hMSC from 6 different donors with osteogenic medium for
1, 7 and 14 days in the absence and presence of rhSAA1 (Fig. 4). Stan-
dard osteogenic media alone signiﬁcantly stimulated endogenous
SAA1 and 2 expression compared to undifferentiated controls. This ef-
fectwas enhanced by day 1 butwas abolished by day 14 in the presence
of exogenous rhSAA1 (Fig. 4). Very similar patterns, e.g. an increase dur-
ing osteogenic differentiation compared to undifferentiated controls,
were observed for TLR2, TLR4, ROR2, IBSP, WNT5a and OP although an
increase within the time frame of osteogenic differentiation could only
be reported for OP and IBSP (Fig. 4, black lines). In the presence of
rhSAA1 the rise of expression along osteogenic differentiation was
shifted to earlier time points, possibly indicating an inﬂammation-
associated acceleration of osteogenic differentiation. Gene expression
of osteoblasticmarkers such as RUNX2 (runt-related transcription factor
2) and IBSP (bone sialoprotein II) was enhanced by rhSAA1 at early time
points while OP (osteopontin) was not changed (Fig. 4, dotted lines).
3.5. rhSAA1 enhances mineralization during osteogenic differentiation
in vitro
In order to clarify if the accelerated and enhanced pro-inﬂammatory
microenvironment leads to enhanced early (4 to 7 days) and late (2 to3 weeks) functional readouts of osteogenic differentiation we analyzed
late in vitro ALP activity and mineralization under continuous rhSAA1
stimulation in 8 different hMSC donors. For early effects and to conﬁrm
TLR4 dependent signaling 3 different hMSC donors were stimulated
with rhSAA1 and costimulated with the TLR4 inhibitor CLI-095.
After 4 days of stimulationwith rhSAA1 in osteogenic differentiation
media (OM) ALP activity was signiﬁcantly enhanced compared to cells
cultivated in OM alone (Figs. 5A and B). TLR4 inhibition with CLI-095
signiﬁcantly abrogated the effect induced by rhSAA1, and CLI-095
alone had no impact on ALP activity (Figs. 5A and B). For long-term
effects ALP activity was analyzed after 2 weeks and quantiﬁcation of
the ALP staining revealed no difference between OM and OM +
rhSAA1 cultivated cells (data not shown).
After 7 days of stimulating cells with rhSAA1 in OM Alizarin Red S
staining visualized the beginning of mineralization, which was
completely absent in cells cultivated in OM alone (Fig. 5C). Cotreatment
with the TLR4 inhibitor CLI-095 abrogated this effect, which was con-
ﬁrmed by quantitative analysis of the mineralized area (Fig. 5D). CLI-
095 alone had no inﬂuence on mineralization. For long-term effects,
after 3 weeks in OM, we also conﬁrmed a higher mineralization level
in rhSAA1 treated cells as visualized by Alizarin Red S staining
(Fig. 5E) and quantiﬁcation of the mineralized area (Fig. 5F).
4. Discussion
Toll like receptors like TLR2 and 4 are importantmediators of inﬂam-
mation, differentiation and aging in bone marrow derived mesenchy-
mal stem cells (hMSCs) (Delarosa et al., 2012). Chronic inﬂammation
has been associated with cellular and organismal aging and the term
“inﬂammaging” has been coined for this phenomenon (Franceschi
et al., 2007). Micro-RNAs have recently been discussed to dysregulate
TLR activation and the consecutive propagation of a senescence associ-
ated secretory phenotype (SASP), which comprises stimulation of pro-
inﬂammatory cytokine secretion such as IL1β, IL8 and of a distinct
pattern of metalloproteinases (Brown et al., 2011; Olivieri et al., 2013).
Serum amyloid protein is another stimulator of inﬂammation that is se-
creted by the liver in large amounts in response to injury and infection.
However it can also be locally produced in diseases such as rheumatoid
arthritis, osteoarthritis and atherosclerosis (Kovacevic et al., 2008;
Vallon et al., 2001; de Seny et al., 2013; Meek et al., 1994; Eklund
et al., 2012). TLR2 and TLR4 have been shown to be functional receptors
for SAA (Cheng et al., 2008; Sandri et al., 2008). Here we show that SAA
is increasingly produced by hMSC during in vitro aging. In this situation
SAA expression is associated with the development of a SASP and the
rising expression of e.g. IL1β, IL8 and OPG in aging hMSCs (Figs. 1 and
3 and reported in Ren et al. (2013)). In order to establish a causal rela-
tionship between those two phenomena we stimulated early passage
hMSC with rhSAA1 and we could induce cytokine production after
24 h resembling a SASP phenotype, even in cells that so far have not
yet been presenescent. Moreover, rhSAA1 stimulated the endogenous
production of SAA1 and 2 thus propagating an autocrine feedback
loop, which is capable of sustaining and amplifying a proinﬂammatory
microenvironment. We conclude therefrom that both endogenous and
exogenous SAA can stimulate the SASP in natural defense and in disease
in hMSC and can propagate cellular aging and replicative senescence.
Our results in this model of in vitro aging of hMSC closely resemble
the concept established by Rodier and Campisi, which describes the de-
velopment of an increasingly complex and self-sustaining secretory
phenotype that ceases at the very moment of established cellular
aging and may have implications for tumor development and other
age-associated diseases (Rodier and Campisi, 2011). Endogenous and
exogenous SAA may be a novel stimulator and orchestrator of this pro-
cess, which is a self-sustaining one in several aspects like ampliﬁcation
of the proinﬂammatory cascade through several players, but also
through paracrine spreading of the SASP and of presenescence. One
important self-sustaining component is for example inﬂammasome
Fig. 4. Osteogenic differentiation and gene expression. rhSAA1 enhances and accelerates mineralization during osteogenic differentiation of hMSC. Gene expression of inﬂammation-as-
sociated genes and osteoblastic markers was analyzed after 1, 7 and 14 days of osteogenic differentiation (black line) and after osteogenic differentiation in the presence of 1 μM rhSAA1
(dotted line). Lines represent themeans of changes in expression± SD of 6 hMSC populations compared to undifferentiated control cells at the respective time point. *p b 0.05, **p b 0.01,
and ***p b 0.001. Signiﬁcances were also calculated for the effect of rhSAA1 on osteogenic differentiation (#p b 0.05, ###p b 0.001 with REST (Pfafﬂ et al., 2002)). (IBSP: integrin-binding
sialoprotein; IL1B: interleukin 1 beta, IL6: interleukin 6, IL8: interleukin 8; OP: osteopontin; ROR2: receptor tyrosine kinase-like orphan receptor 2; RUNX2: runt-related transcription fac-
tor 2; SAA1: serum amyloid A1; SAA2: serum amyloid A2; TLR2: toll-like receptor 2; TLR4: toll-like receptor 4; WNT5A: wingless-type MMTV integration site family, member 5A).
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further orchestrates inﬂammasome activation. Not only is this process
self-sustaining but it is also “infectious” as it has been demonstrated
by Acosta et al. in a recent paper, where they coined the term “paracrine
senescence” (Acosta et al., 2013). We propose that SAA can be added to
the players, which can initiate and amplify autocrine and paracrine
senescence.
In contrast to chronic TLR activation and inﬂammation, short
time stimulation of the innate immune system may have completely
different tasks with respect to tissue maturation and repair. It is well
known that bone healing during fracture repair is induced by platelet
derived growth factor stimulation after injury, followed by an inﬂam-
matory phase that precedes the osteogenic and the remodeling phases(Kolar et al., 2010; Ai-Aql et al., 2008). Osteogenic non-canonical wnt-
signaling through WNT5A secretion is stimulated by proinﬂammatory
stimuli (Rauner et al., 2012). We therefore hypothesized that both the
endogenous production of SAA and exogenous SAA exposure during in-
jury and infection maymodulate the osteogenic differentiation process.
During in vitro osteogenic differentiation using established osteogenic
media SAA1 and 2 are both stimulated and this is associated with a
very similar proinﬂammatory phenotype observed in our aging model.
The peak of the expression is however early in the course of osteogenic
differentiation and seems to cease at later time points. Whenwe on top
added rhSAA1 to these routine osteogenic differentiation experiments
we observed a marked acceleration of the induction of osteogenic
differentiation and the pro-inﬂammatory phenotype (Fig. 4). We also
Fig. 5.Osteogenic differentiation andmineralization. HumanMSCs were treatedwith osteogenicmedia (OM), OM+1 μM rhSAA1, OM+1 μM rhSAA1+ CLI-095 andOM+CLI-095 and
ALP staining and the mineralized matrix per area was quantiﬁed. Panel (A) shows the representative images of ALP staining after 4 days. (B) Quantiﬁcation of ALP staining (3 individual
MSC donors, 6 images each) was performed after osteogenic differentiation for 4 days. Panel (C) shows the representative images of Alizarin Red S stainedmineralizedmatrix after 7 days
of osteogenic differentiation, length of bar represents 200 μM.Mineralization was quantiﬁed in 3 donors, 6 images each (D). (E) HumanMSCs were treated with osteogenic media (OM)
and OM+1 μM rhSAA1 for 3weeks and ﬁxed and stainedwith Alizarin Red S. Representative images are shown, length of bar indicates 200 μm. (F) The amount ofmineralizedmatrix per
area was quantiﬁed for hMSC of 8 donors, 20 images each. (*p b 0.05 and **p b 0.005 byWilcoxon signed-ranks test).
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signaling and stimulation of osteogenic differentiation, are direct targets
of TLR4 activation during osteogenic differentiation. Mechanistically
this involved p38 and p65 phosphorylation and NFκB activation. We
conclude from these data that in the early phase of bone regeneration
and fracture healing the process of osteogenic differentiation is directly
enhanced by TLR4 activation (conﬁrmed by using the TLR4 inhibitor
CLI-095) via autocrine and paracrine SAA1 and 2 production and
their downstream targets, which again amplify the WNT5A induction
demonstrated earlier (Rauner et al., 2012).
Mineralization is a hallmark of osteogenic differentiation, which is
orchestrated by a set of genes and their substrates/products such as
alkaline phosphatase and other ectophosphatases, phospho 1, ENPP
and the calciﬁcation inhibitors osteopontin, FGF23 and osteocalcin,
which propagate or inhibit crystallization to guarantee a coordinated
mineralization process (Harmey et al., 2004). In order to characterize
early and late osteogenic readouts under the inﬂuence of SAA we
analyzed in vitro ALP activity and mineralization and we were able to
demonstrate that early ALP activity and early and late mineralization
aremarkedly enhanced in thepresence of rhSAA1. This identical process
could also be induced in osseous and extraosseous pathological calciﬁ-
cation processes where SAA expression has been described. Hence
SAA could also be tightly involved in calcifying inﬂammatory reactions
such as we can see in atherosclerosis or in sclerosing bone metastases
as frequently seen in prostate and breast cancer bone metastases,
where also WNT5A is an important marker (Thiele et al., 2011; Zhang
et al., 2012; Hansen et al., 2015; Le et al., 2005).
5. Conclusion
In summarywe showhere, that SAA is locally produced bymesenchy-
mal stem cells both during in vitro aging and in early phases of in vitroosteogenic differentiation. SAA is capable of inducing the expression of
an SASP resembling phenotype, which is either accelerating/enhancing
osteogenic differentiation and mineralization, or induces the SASP that
precedes replicative senescence. SAAmay thus be involved in physiologic
mineralization during bone formation, in pathologic calciﬁcation in
degenerative age-associated diseases such as atherosclerosis and
sclerosing bonemetastases of e.g. breast andprostate cancers. SAA signals
via p38 phosphorylation and p65/NFκB activation after binding to
TLR4. Prolonged and pathological activation of this self-sustaining and
self-amplifying loop can principally be targeted by TLR4 inhibitors but
possibly with a substantial risk of interfering with principles of
regeneration.
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doi.org/10.1016/j.scr.2015.06.008.Acknowledgments
This work was supported by the German Research Foundation
(FOR793 JA506/9-1 and in part by FOR1586 SKELMET). We thank
Martina Regensburger for technical assistance and the orthopedic sur-
geons who supplied us with human femoral head material.References
Acosta, J.C., Banito, A., Wuestefeld, T., Georgilis, A., Janich, P., Morton, J.P., Athineos, D.,
Kang, T.W., Lasitschka, F., Andrulis, M., Pascual, G., Morris, K.J., Khan, S., Jin, H.,
Dharmalingam, G., Snijders, A.P., Carroll, T., Capper, D., Pritchard, C., Inman, G.J.,
Longerich, T., Sansom, O.J., Benitah, S.A., Zender, L., Gil, J., 2013. A complex secretory
program orchestrated by the inﬂammasome controls paracrine senescence. Nat.
Cell Biol. 15, 978–990.
Ai-Aql, Z.S., Alagl, A.S., Graves, D.T., Gerstenfeld, L.C., Einhorn, T.A., 2008. Molecular
mechanisms controlling bone formation during fracture healing and distraction
osteogenesis. J. Dent. Res. 87, 107–118.
239R. Ebert et al. / Stem Cell Research 15 (2015) 231–239Baron, R., Kneissel, M., 2013. WNT signaling in bone homeostasis and disease: from
human mutations to treatments. Nat. Med. 19, 179–192.
Benisch, P., Schilling, T., Klein-Hitpass, L., Frey, S.P., Seefried, L., Raaijmakers, N., Krug, M.,
Regensburger, M., Zeck, S., Schinke, T., Amling, M., Ebert, R., Jakob, F., 2012. The tran-
scriptional proﬁle of mesenchymal stem cell populations in primary osteoporosis is
distinct and shows overexpression of osteogenic inhibitors. PLoS One 7, e45142.
Brown, J., Wang, H., Hajishengallis, G.N., Martin, M., 2011. TLR-signaling networks: an
integration of adaptor molecules, kinases, and cross-talk. J. Dent. Res. 90, 417–427.
Chang, J., Liu, F., Lee, M., Wu, B., Ting, K., Zara, J.N., Soo, C., Al Hezaimi, K., Zou,W., Chen, X.,
Mooney, D.J., Wang, C.Y., 2013. NF-kappaB inhibits osteogenic differentiation of
mesenchymal stem cells by promoting beta-catenin degradation. Proc. Natl. Acad.
Sci. U. S. A. 110, 9469–9474.
Cheng, N., He, R., Tian, J., Ye, P.P., Ye, R.D., 2008. Cutting edge: TLR2 is a functional receptor
for acute-phase serum amyloid A. J. Immunol. 181, 22–26.
Christman 2nd, M.A., Goetz, D.J., Dickerson, E., McCall, K.D., Lewis, C.J., Benencia, F., Silver,
M.J., Kohn, L.D., Malgor, R., 2008. Wnt5a is expressed in murine and human athero-
sclerotic lesions. Am. J. Physiol. Heart Circ. Physiol. 294, H2864–H2870.
de Seny, D., Cobraiville, G., Charlier, E., Neuville, S., Esser, N., Malaise, D., Malaise, O., Calvo,
F.Q., Relic, B., Malaise, M.G., 2013. Acute-phase serum amyloid a in osteoarthritis:
regulatory mechanism and proinﬂammatory properties. PLoS One 8, e66769.
DelaRosa, O., Lombardo, E., 2010. Modulation of adult mesenchymal stem cells activity by
toll-like receptors: implications on therapeutic potential. Mediat. Inﬂamm. 2010,
865601.
Delarosa, O., Dalemans, W., Lombardo, E., 2012. Toll-like receptors as modulators of
mesenchymal stem cells. Front. Immunol. 3, 182.
Dong, Z., An, F., Wu, T., Zhang, C., Zhang, M., Zhang, Y., An, G., An, F., 2011. PTX3, a key
component of innate immunity, is induced by SAA via FPRL1-mediated signaling in
HAECs. J. Cell. Biochem. 112, 2097–2105.
Ebert, R., Zeck, S., Krug, R., Meissner-Weigl, J., Schneider, D., Seefried, L., Eulert, J., Jakob, F.,
2009. Pulse treatment with zoledronic acid causes sustained commitment of bone
marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 44,
858–864.
Eklund, K.K., Niemi, K., Kovanen, P.T., 2012. Immune functions of serum amyloid A. Crit.
Rev. Immunol. 32, 335–348.
Franceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M.P., Invidia,
L., Celani, L., Scurti, M., Cevenini, E., Castellani, G.C., Salvioli, S., 2007. Inﬂammaging
and anti-inﬂammaging: a systemic perspective on aging and longevity emerged
from studies in humans. Mech. Ageing Dev. 128, 92–105.
Gerstenfeld, L.C., Cho, T.J., Kon, T., Aizawa, T., Tsay, A., Fitch, J., Barnes, G.L., Graves, D.T.,
Einhorn, T.A., 2003. Impaired fracture healing in the absence of TNF-alpha signaling:
the role of TNF-alpha in endochondral cartilage resorption. J. Bone Miner. Res. 18,
1584–1592.
Hagihara, K., Nishikawa, T., Isobe, T., Song, J., Sugamata, Y., Yoshizaki, K., 2004. IL-6 plays a
critical role in the synergistic induction of human serum amyloid A (SAA) gene when
stimulated with proinﬂammatory cytokines as analyzed with an SAA isoform real-
time quantitative RT-PCR assay system. Biochem. Biophys. Res. Commun. 314,
363–369.
Hansen, M.T., Forst, B., Cremers, N., Quagliata, L., Ambartsumian, N., Grum-Schwensen, B.,
Klingelhofer, J., Abdul-Al, A., Herrmann, P., Osterland, M., Stein, U., Nielsen, G.H.,
Scherer, P.E., Lukanidin, E., Sleeman, J.P., Grigorian, M., 2015. A link between inﬂam-
mation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets
of metastasis-inducing S100A4. Oncogene 34, 424–435.
Harmey, D., Hessle, L., Narisawa, S., Johnson, K.A., Terkeltaub, R., Millan, J.L., 2004.
Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1,
and ank: an integrated model of the pathogenesis of mineralization disorders. Am.
J. Pathol. 164, 1199–1209.
Hofbauer, L.C., Rachner, T.D., Coleman, R.E., Jakob, F., 2014. Endocrine aspects of bone
metastases. Lancet Diabetes Endocrinol. 2, 500–512.
Huang, R., Yuan, Y., Zou, G.M., Liu, G., Tu, J., Li, Q., 2014. LPS-stimulated inﬂammatory
environment inhibits BMP-2-induced osteoblastic differentiation through crosstalk
between TLR4/MyD88/NF-kappaB and BMP/Smad signaling. Stem Cells Dev. 23,
277–289.
Kang, J.Y., Lee, J.O., 2011. Structural biology of the Toll-like receptor family. Annu. Rev.
Biochem. 80, 917–941.
Kolar, P., Schmidt-Bleek, K., Schell, H., Gaber, T., Toben, D., Schmidmaier, G., Perka, C.,
Buttgereit, F., Duda, G.N., 2010. The early fracture hematoma and its potential role
in fracture healing. Tissue Eng. Part B Rev. 16, 427–434.Kovacevic, A., Hammer, A., Stadelmeyer, E., Windischhofer, W., Sundl, M., Ray, A.,
Schweighofer, N., Friedl, G., Windhager, R., Sattler, W., Malle, E., 2008. Expression of
serum amyloid A transcripts in human bone tissues, differentiated osteoblast-like
stem cells and human osteosarcoma cell lines. J. Cell. Biochem. 103, 994–1004.
Le, L., Chi, K., Tyldesley, S., Flibotte, S., Diamond, D.L., Kuzyk, M.A., Sadar, M.D., 2005.
Identiﬁcation of serum amyloid A as a biomarker to distinguish prostate cancer
patients with bone lesions. Clin. Chem. 51, 695–707.
Meek, R.L., Urieli-Shoval, S., Benditt, E.P., 1994. Expression of apolipoprotein serum amy-
loid A mRNA in human atherosclerotic lesions and cultured vascular cells: implica-
tions for serum amyloid A function. Proc. Natl. Acad. Sci. U. S. A. 91, 3186–3190.
Mo, I.F., Yip, K.H., Chan, W.K., Law, H.K., Lau, Y.L., Chan, G.C., 2008. Prolonged exposure to
bacterial toxins downregulated expression of toll-like receptors in mesenchymal
stromal cell-derived osteoprogenitors. BMC Cell Biol. 9, 52.
Olivieri, F., Rippo, M.R., Prattichizzo, F., Babini, L., Graciotti, L., Recchioni, R., Procopio, A.D.,
2013. Toll like receptor signaling in “inﬂammaging”: microRNA as new players.
Immun. Ageing 10, 11.
Pevsner-Fischer, M., Morad, V., Cohen-Sfady, M., Rousso-Noori, L., Zanin-Zhorov, A.,
Cohen, S., Cohen, I.R., Zipori, D., 2007. Toll-like receptors and their ligands control
mesenchymal stem cell functions. Blood 109, 1422–1432.
Pfafﬂ, M.W., 2001. A new mathematical model for relative quantiﬁcation in real-time
RT-PCR. Nucleic Acids Res. 29, e45.
Pfafﬂ, M.W., Horgan, G.W., Dempﬂe, L., 2002. Relative expression software tool (REST)
for group-wise comparison and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30, e36.
Raicevic, G., Najar, M., Pieters, K., De Bruyn, C., Meuleman, N., Bron, D., Toungouz, M.,
Lagneaux, L., 2012. Inﬂammation and Toll-like receptor ligation differentially affect
the osteogenic potential of human mesenchymal stromal cells depending on their
tissue origin. Tissue Eng. A 18, 1410–1418.
Rauner, M., Stein, N., Winzer, M., Goettsch, C., Zwerina, J., Schett, G., Distler, J.H., Albers, J.,
Schulze, J., Schinke, T., Bornhauser, M., Platzbecker, U., Hofbauer, L.C., 2012. WNT5A
is induced by inﬂammatory mediators in bone marrow stromal cells and regulates
cytokine and chemokine production. J. Bone Miner. Res. 27, 575–585.
Ren, J., Stroncek, D.F., Zhao, Y., Jin, P., Castiello, L., Civini, S., Wang, H., Feng, J., Tran, K.,
Kuznetsov, S.A., Robey, P.G., Sabatino, M., 2013. Intra-subject variability in human
bone marrow stromal cell (BMSC) replicative senescence: molecular changes associ-
ated with BMSC senescence. Stem Cell Res. 11, 1060–1073.
Rodier, F., Campisi, J., 2011. Four faces of cellular senescence. J. Cell Biol. 192, 547–556.
Rolls, A., Shechter, R., London, A., Ziv, Y., Ronen, A., Levy, R., Schwartz, M., 2007. Toll-like
receptors modulate adult hippocampal neurogenesis. Nat. Cell Biol. 9, 1081–1088.
Sandri, S., Rodriguez, D., Gomes, E., Monteiro, H.P., Russo, M., Campa, A., 2008. Is serum
amyloid A an endogenous TLR4 agonist? J. Leukoc. Biol. 83, 1174–1180.
Su, S.B., Gong, W., Gao, J.L., Shen, W., Murphy, P.M., Oppenheim, J.J., Wang, J.M., 1999. A
seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic
activity of serum amyloid A for human phagocytic cells. J. Exp. Med. 189, 395–402.
Thiele, S., Rauner, M., Goettsch, C., Rachner, T.D., Benad, P., Fuessel, S., Erdmann, K.,
Hamann, C., Baretton, G.B., Wirth, M.P., Jakob, F., Hofbauer, L.C., 2011. Expression pro-
ﬁle ofWNTmolecules in prostate cancer and its regulation by aminobisphosphonates.
J. Cell. Biochem. 112, 1593–1600.
Thorn, C.F., Lu, Z.Y., Whitehead, A.S., 2004. Regulation of the human acute phase serum
amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids
in hepatic and epithelial cell lines. Scand. J. Immunol. 59, 152–158.
Vallon, R., Freuler, F., Desta-Tsedu, N., Robeva, A., Dawson, J., Wenner, P., Engelhardt, P.,
Boes, L., Schnyder, J., Tschopp, C., Urfer, R., Baumann, G., 2001. Serum amyloid A
(apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcrip-
tion of matrix metalloproteinases. J. Immunol. 166, 2801–2807.
Velarde, M.C., Demaria, M., Campisi, J., 2013. Senescent cells and their secretory pheno-
type as targets for cancer therapy. Interdiscip. Top. Gerontol. 38, 17–27.
Yang, H., Kong, X., Wei, J., Liu, C., Song, W., Zhang, W., Wei, W., He, S., 2012. Cockroach al-
lergen Per a 7 down-regulates expression of Toll-like receptor 9 and IL-12 release
from P815 cells through PI3K and MAPK signaling pathways. Cell. Physiol. Biochem.
29, 561–570.
Zhang, G., Sun, X., Lv, H., Yang, X., Kang, X., 2012. Serum amyloid A: a new potential serum
marker correlated with the stage of breast cancer. Oncol. Lett. 3, 940–944.
Zhao, L., Huang, J., Zhang, H.,Wang, Y., Matesic, L.E., Takahata, M., Awad, H., Chen, D., Xing,
L., 2011. Tumor necrosis factor inhibits mesenchymal stem cell differentiation into
osteoblasts via the ubiquitin E3 ligase Wwp1. Stem Cells 29, 1601–1610.
